Search results for "Remission"

showing 10 items of 213 documents

Complete biochemical control and pituitary adenoma disappearance in a child with gigantism: Efficacy of octreotide therapy

2011

medicine.medical_specialtymedicine.diagnostic_testbusiness.industryEndocrinology Diabetes and MetabolismTreatment outcomeOctreotideMagnetic resonance imagingmedicine.diseaseGastroenterologyGigantismSettore MED/13 - EndocrinologiaRemission inductionEndocrinologyEndocrinologygigantism octreotidePituitary adenomaInternal medicineMedicinebusinessmedicine.drug
researchProduct

A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation.

2020

Successful discontinuation of tyrosine kinase inhibitors has been achieved in patients with chronic-phase chronic myeloid leukemia (CML). Careful molecular monitoring after discontinuation warrants safe and prompt resumption of therapy. We retrospectively evaluated how molecular monitoring has been conducted in Italy in a cohort of patients who discontinued tyrosine kinase inhibitor (TKI) treatment per clinical practice. The outcome of these patients has recently been reported&mdash

medicine.medical_specialtymedicine.drug_classlcsh:MedicineTyrosine-kinase inhibitorArticle03 medical and health sciences0302 clinical medicinechronic myeloid leukemiahemic and lymphatic diseasesInternal medicineRetrospective analysisMedicineIn patientchronic myeloid leukemia; treatment-free remission; molecular monitoringtreatment-free remissionbusiness.industrylcsh:RMyeloid leukemiaGeneral MedicineDiscontinuationmolecular monitoringchronic myeloid leukemia; molecular monitoring; treatment-free remission030220 oncology & carcinogenesisMajor Molecular ResponseCohortbusinessOff Treatment030215 immunologyJournal of clinical medicine
researchProduct

The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guideline…

2010

Biological therapies are an important step in the management of Inflammatory Bowel Diseases. In consideration of high cost and safety issues there is the need to have clear recommendations for their use. Despite the American Gastroenterological Association and the European Crohn's and Colitis Organisation have published exhaustive Inflammatory Bowel Disease guidelines, national guidelines may be necessary as cultural values, economical and legal issues may differ between countries. For these reasons the Italian Society of Gastroenterology and the Italian Group for the study of Inflammatory Bowel Disease have decided to elaborate the Italian guidelines on the use of biologics in Inflammatory…

methods Tumor Necrosis Factor-alphaAnti-Inflammatory AgentsUlcerativeDiseaseGUIDELINESHumanized Antibodieetiology Pregnancy Pregnancy ComplicationGastroenterologyInflammatory bowel diseaseetiology Opportunistic InfectionCrohn DiseasePregnancyNeoplasmsMonoclonaldrug therapy Remission Inductionantagonists /&/ inhibitorsSettore MED/12 - GastroenterologiaRemission InductionGastroenterologyAntibodies MonoclonalUlcerative colitisAnti-Inflammatory AgentItalyadverse effects/therapeutic use Intestinal FistulaTumor necrosis factor alphaFemaleImmunosuppressive Agentsmedicine.drugbiological drugsmedicine.medical_specialtyIBDOpportunistic InfectionsAntibodies Monoclonal HumanizedAutoimmune Diseasesadverse effects/therapeutic use Autoimmune DiseaseInternal medicinemedicineAdalimumabIntestinal FistulaHumansColitisdiagnosis/drug therapy/surgery Italy Neoplasmadverse effects/therapeutic use AntibodieHepatologydrug therapy Female Humans Immunosuppressive Agentbusiness.industryTumor Necrosis Factor-alphaAdalimumabCancermedicine.diseaseInfliximabInfliximabdigestive system diseasesdrug therapy Crohn Diseaseetiology ColitiPregnancy ComplicationsColitis Ulcerativebusiness
researchProduct

Adalimumab in active ulcerative colitis: A “real-life” observational study

2013

Abstract Background and aims The effectiveness of adalimumab in the treatment of ulcerative colitis is under debate. Although controlled trials have shown that adalimumab is significantly better than placebo, the absolute clinical benefit is modest. We report data on the effectiveness of adalimumab in a cohort of ulcerative colitis patients treated in 22 Italian centres. Methods All patients with active disease treated with adalimumab were retrospectively reviewed. Co-primary endpoints were clinical remission at weeks 4, 12, 24 and 54. Secondary endpoints were sustained clinical remission, steroid discontinuation, endoscopic remission and need for colectomy. Results Eighty-eight patients we…

musculoskeletal diseasesAdultMaleAdalimumab “Real-life” study Ulcerative colitismedicine.medical_specialtymedicine.medical_treatmentIBDAnti-Inflammatory AgentsAdalimumab; “Real-life” study; Ulcerative colitisAntibodies Monoclonal HumanizedPlaceboCohort StudiesYoung AdultRefractoryAdrenal Cortex HormonesInternal medicineAdalimumabmedicineHumansskin and connective tissue diseases“Real-life” studyRetrospective StudiesColectomySettore MED/12 - GastroenterologiaHepatologybusiness.industryRemission InductionSettore MED/09 - MEDICINA INTERNAGastroenterologyAdalimumabmedicine.diseaseUlcerative colitishumanitiesInfliximabSurgeryDiscontinuationTreatment OutcomeUlcerative colitisCohortColitis UlcerativeDrug Therapy CombinationFemalebusinessmedicine.drug
researchProduct

Self-reported flares are predictors of radiographic progression in rheumatoid arthritis patients in 28-joint disease activity score remission: a 24-m…

2016

Background Disease flares are common in rheumatoid arthritis (RA) and are related to structural damage. However, few data on the impact of flares reported by patients on radiographic progression are available. Our aim was to investigate whether overall flares (OF), self-reported flares (SRF) and short flares assessed at the visit (SF) predict radiographic progression in RA patients in DAS28 (28-joint disease activity score) remission. Methods We reviewed the records of RA patients included in our database. We considered all patients who had a period of at least 24 months in remission (DAS28 0. Patients were assessed every 3 months and flares were recorded. We defined SRF as any worsening of…

musculoskeletal diseasesmedicine.medical_specialtyRadiographic progressionRadiographyDiseasenot knownDisease activity03 medical and health sciencesJoint disease0302 clinical medicineInternal medicineDAS28 remissionmedicine030212 general & internal medicineRheumatoid arthritisskin and connective tissue diseases030203 arthritis & rheumatologybusiness.industryFlaresmedicine.diseaseRheumatologyBiologic treatment; DAS28 remission; Flares; Radiographic progression; Rheumatoid arthritis; Self-reported flaresRheumatoid arthritisOrthopedic surgeryPhysical therapyObservational studybusinessBiologic treatmentSelf-reported flaresResearch ArticleArthritis Research & Therapy
researchProduct

Early Treatment of Systemic Juvenile Idiopathic Arthritis with Canakinumab and Complete Remission After 2 Years of Treatment Suspension: Case Report …

2019

Systemic juvenile idiopathic arthritis (sJIA) is an autoinflammatory disease characterised by fever and arthritis. We describe the case of a 14-year-old girl hospitalised with fever associated with rash, myalgia, arthralgia and polyarticular involvement. Examinations revealed increased levels of C-reactive protein, erythrocyte sedimentation rate, ferritin, triglycerides, leukocytes, neutrophils, lactate dehydrogenase, fibrinogen, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and γ-glutamyl transferase (GGT). Bone marrow biopsy showed polyclonal leukocyte activation. A genetic study revealed a heterozygous mutation of the MEFV gene, c.442G>C (E148Q), which is typical of…

myalgiaAbdominal painmedicine.medical_specialtyTime FactorsAdolescentCanakinumabFamilial Mediterranean feverArthritisCase Report030204 cardiovascular system & hematologyAntibodies Monoclonal Humanized030226 pharmacology & pharmacyGastroenterology03 medical and health sciences0302 clinical medicineautoinflammatory diseaseInternal medicinemedicineHumansPharmacology (medical)medicine.diagnostic_testbusiness.industryRemission InductionAntibodies MonoclonalGeneral MedicineExanthemamedicine.diseaseMEFVRashdigestive system diseasesArthritis JuvenileCanakinumabTreatment OutcomeErythrocyte sedimentation rateSystemic juvenile idiopathic arthritiFemalemedicine.symptombusinessmedicine.drug
researchProduct

La remissione del debito. Artt. 1236-1240

2018

Il volume prende in esame la disciplina della remissione del debito, prevista dagli artt. 1236-1240 c.c., e pone in evidenza i problemi che le disposizioni ivi contemplate sollevano all’interprete. Di ciascuno di tali problemi sono illustrati le soluzioni fornite dalla dottrina e dalla giurisprudenza, e gli argomenti a sostegno della proposta interpretativa che, relativamente a ciascun profilo dell’istituto, viene reputata come la più convincente. The volume consideres the discipline of the remission of the debt, as provided for in articles 1236-1240 c.c., and it highlights the interpretative problems. The solutions of the doctrine, the jurisprudence and the proposals more convincing (relat…

remissione del debito rinunzia al credito restituzione volontaria del titolo rinunzia alle garanzierinunzia al creditorinunzia alle garanzieSettore IUS/01 - Diritto PrivatoSettore IUS/15 - Diritto Processuale Civilerestituzione volontaria del titoloremissione del debito
researchProduct

The Clinical Value of Autoantibodies in Rheumatoid Arthritis

2018

Rheumatoid arthritis (RA) is a highly heterogeneous syndrome in terms of clinical presentation, progression, and response to therapy. In such a complicated context, the identification of disease-related biomarkers would be undoubtedly helpful in assisting tailored approaches for every patient. Despite remarkable efforts, however, progress in new biomarker development and validation is dramatically slow. At present, none of the candidate genetic, cellular, or molecular biomarker has yet surpassed the clinical value of RA-specific autoantibodies, including rheumatoid factor (RF) and anti-citrullinated protein autoantibodies (ACPA). Rather, recent years have witnessed significant advancements …

rheumatoid arthritis0301 basic medicineResponse to therapyautoantibodiesMini ReviewContext (language use)Bioinformaticsrheumatoid factor03 medical and health sciencesremission0302 clinical medicinemedicineRheumatoid factoranti-citrullinated protein antibodies030203 arthritis & rheumatologylcsh:R5-920biologybusiness.industryAutoantibodyAnti–citrullinated protein antibodyGeneral Medicinemedicine.disease030104 developmental biologyRheumatoid arthritisbiology.proteinClinical valueMedicineBiomarker (medicine)lcsh:Medicine (General)businessFrontiers in Medicine
researchProduct

Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-α blockers: The GI…

2007

OBJECTIVE: To assess the prevalence of good clinical response and remission in rheumatoid arthritis (RA) patients with longstanding disease treated with anti-tumor necrosis factor-alpha (TNF-alpha) drugs at outpatient clinics. METHODS: Retrospective national study of 14 academic tertiary referral rheumatology medical centers. RA patients with a Disease Activity Score (DAS28) > 3.2 were defined as having active disease and could start TNF-alpha blockers. All patients received one TNF-alpha blocker plus methotrexate (10-20 mg/wk). At the third month the patients were categorized as responders or nonresponders, based on improvement of at least 0.25 of the Health Assessment Questionnaire (HAQ).…

rheumatoid arthritisAdultMaleQuality Assurance Health Carepredictors of remissionTumor Necrosis Factor blockersAntibodies Monoclonal HumanizedSeverity of Illness IndexReceptors Tumor Necrosis FactorEtanerceptArthritis RheumatoidRheumatoid arthritis; Good clinical response; Tumor Necrosis Factor blockersPredictive Value of TestsHumansRheumatoid arthritispredictors of remission; rheumatoid arthritis; tumor necrosis factor-alpha blockersAgedRetrospective StudiesGood clinical responseTumor Necrosis Factor-alphatumor necrosis factor-alpha blockersRemission InductionAdalimumabAntibodies MonoclonalMiddle AgedPrognosisInfliximabLogistic ModelsMethotrexateTreatment Outcomedisability score; good clinical response; remission; rheumatoid arthritis; tumor necrosis factor-α blockersItalyAntirheumatic AgentsImmunoglobulin GFemale
researchProduct

Il contratto di remissione del debito

2015

Il punto di partenza per la comprensione della struttura della remissione del debito è costituito dalla verifica della correttezza del metodo interpretativo che valorizza il profilo teleologico dello specifico rapporto obbligatorio preso in esame, sottolineando la rilevanza dell’individuazione delle peculiarità della rosa di interessi ad esso sottesi. È indispensabile cogliere la funzione che caratterizza la remissione del debito per accertare, da un lato, se essa costituisca l’unico schema di rinuncia relativo ai diritti di credito e, dall’altro, se la struttura della remissione sia sempre la stessa oppure muti a seconda di quali siano gli interessi concreti del determinato rapporto obblig…

rinunzia al creditoSettore IUS/01 - Diritto Privatoremissione del debito rinunzia al creditoremissione del debito
researchProduct